[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-342494-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-342494-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","the-xcl1-mediated-dna-vaccine-targeting-type-1-conventional-dendritic-cells-combined-with-gemcitabine-and-anti-pd1-antibody-induces-potent-antitumor-immunity-in-a-mouse-lung-cancer-model","The XCL1-Mediated DNA Vaccine Targeting Type 1 Conventional Dendritic Cells Combined with Gemcitabine and Anti-PD1 Antibody Induces Potent Antitumor Immunity in a Mouse Lung Cancer Model","","Cancer immunotherapy increasingly relies on vaccines to stimulate cellular immunity, yet DNA vaccines remain constrained by limited immunogenicity and only modest therapeutic benefit across many tumor types. This study highlights Type 1 conventional dendritic cells (cDC1), which cross-present vaccine antigens to activate CD8+ T cells, as central to DNA vaccine antitumor activity. A cDC1-targeting strategy fuses XCL1 to DNA vaccine antigens and evaluates it alone and in combination with gemcitabine and anti-PD1 in a mouse lung cancer model. Results show enhanced immunogenicity and improved antitumor efficacy with prolonged survival, supporting clinical investigation of cDC1-targeting DNA vaccines combined with other therapies.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/the-xcl1-mediated-dna-vaccine-targeting-type-1-conventional-dendritic-cells-combined-with-gemcitabine-and-anti-pd1-antibody-induces-potent-antitumor-immunity-in-a-mouse-lung-cancer-model/342494/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/the-xcl1-mediated-dna-vaccine-targeting-type-1-conventional-dendritic-cells-combined-with-gemcitabine-and-anti-pd1-antibody-induces-potent-antitumor-immunity-in-a-mouse-lung-cancer-model/342494.png","ImageObject",300,407,{"name":42,"@type":43},"Patrick","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-13","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",14,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are DNA vaccines considered promising but limited in cancer immunotherapy?","Question",{"text":63,"@type":64},"DNA vaccines can activate antigen-specific cellular immunity, but their effectiveness is often hindered by weak immunogenicity, leading to modest therapeutic outcomes across cancers.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What role do Type 1 conventional dendritic cells (cDC1) play in DNA vaccine efficacy?",{"text":68,"@type":64},"cDC1 cross-present vaccine antigens to activate CD8+ T cells, making them crucial for the antitumor function of DNA vaccines.",{"name":70,"@type":61,"acceptedAnswer":71},"How does combining the cDC1-targeted DNA vaccine with gemcitabine and anti-PD1 affect outcomes in the mouse lung cancer model?",{"text":72,"@type":64},"The combination improves antitumor effect and enhances survival in the mouse lung cancer model, compared with the vaccine approach alone.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},342494,1790154638,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":55,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":26,"preview_urls":146},549758146520,"https://ap-avatar.wpscdn.com/avatar/80002397d8c0411e94?_k=1775819394049821470","Article  \nThe XCL1-Mediated DNA Vaccine Targeting Type 1 Conventional Dendritic Cells Combined with Gemcitabine and Anti-PD1 Antibody Induces Potent Antitumor Immunity in a Mouse Lung Cancer Model  \nKe Zhang 1, Qimuge Wuri 1, Zongyu Cai 1, Xueli Qu 1, Shiqi Zhang 1, Hui Wu 1, Jiaxin Wu 1, Chu Wang 1, Xianghui Yu 1,2, Wei Kong 1,2 and Haihong Zhang 1, *  \nCitation: Zhang, K.; Wuri, Q.; Cai, Z.; Qu, X.; Zhang, S.; Wu, H.; Wu, J.; Wang, C.; Yu, X.; Kong, W.; et al. The XCL1-Mediated DNA Vaccine Targeting Type 1 Conventional Dendritic Cells Combined with Gemcitabine and Anti-PD1 Antibody Induces Potent Antitumor Immunity in a Mouse Lung Cancer Model. Int. J. Mol. Sci. 2024, 25, 1880. [https://](https://)[ ](https://)[doi.org/10.3390/ijms25031880](doi.org/10.3390/ijms25031880)  \nAcademic Editor: Holger Wille  \nReceived: 5 December 2023  \nRevised: 25 January 2024  \nAccepted: 2 February 2024  \nPublished: 4 February 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 National Engineering Laboratory for AIDS Vaccine, School of Life Science, Jilin University, Changchun 130012, China; [zke20@mails.jlu.edu.cn](zke20@mails.jlu.edu.cn) (K.Z.); [wrqmg21@mails.jlu.edu.cn](wrqmg21@mails.jlu.edu.cn) (Q.W.); [caizy22@mails.jlu.edu.cn](caizy22@mails.jlu.edu.cn) (Z.C.); [xlqu21@mails.jlu.edu.cn](xlqu21@mails.jlu.edu.cn) (X.Q.); [sqzhang21@mails.jlu.edu.cn](sqzhang21@mails.jlu.edu.cn) (S.Z.); [topwuhui@jlu.edu.cn](topwuhui@jlu.edu.cn) (H.W.); [wujiaxin@jlu.edu.cn](wujiaxin@jlu.edu.cn) (J.W.); [wangchu18@jlu.edu.cn](wangchu18@jlu.edu.cn) (C.W.); [xianghui@jlu.edu.cn](xianghui@jlu.edu.cn) (X.Y.); [weikong@jlu.edu.cn](weikong@jlu.edu.cn) (W.K.)  \n2 Key Laboratory for Molecular Enzymology and Engineering, The Ministry of Education, School of Life Sciences, Jilin University, Changchun 130012, China  \n* Correspondence: [zhanghh@jlu.edu.cn](zhanghh@jlu.edu.cn)  \nAbstract: With the advent of cancer immunotherapy, there is a growing interest in vaccine development as a means to activate the cellular immune system against cancer. Despite the promise of DNA vaccines in this regard, their effectiveness is hindered by poor immunogenicity, leading to modest therapeutic outcomes across various cancers. The role of Type 1 conventional dendritic cells (cDC1), capable of cross-presenting vaccine antigens to activate CD8+T cells, emerges as crucial for the antitumor function of DNA vaccines. To address the limitations of DNA vaccines, a promising approach involves targeting antigens to cDC1 through the fusion of XCL1, a ligand specific to the receptor XCR1 on the surface of cDC1 . Here, female C57BL/6 mice were selected for tumor inoculation and immunotherapy. Additionally, recognizing the complexity of cancer, this study explored the use of combination therapies, particularly the combination of cDC1-targeted DNA vaccine with the chemotherapy drug Gemcitabine (Gem) and the anti-PD1 antibody in a mouse lung cancer model. The study’s findings indicate that fusion antigens with XCL1 effectively enhance both the immunogenicity and antitumor effects of DNA vaccines. Moreover, the combination of the cDC1-targeted DNA vaccine with Gemcitabine and anti-PD1 antibody in the mouse lung cancer model demonstrates an improved antitumor effect, leading to the prolonged survival of mice. In conclusion, this research provides important support for the clinical investigation of cDC1-targeting DNA vaccines in combination with other therapies.  \nKeywords: immunotherapy; DNA vaccine; cDC1; XCR1; XCL1; gemcitabine; anti-PD1 antibody  \n1. Introduction  \nCancer immunotherapy has witnessed significant strides in the past two decades [1,2] . As the field continues to evolve, it has","cbCaih9O9ROJ8KZ8","https://ap.wps.com/l/cbCaih9O9ROJ8KZ8","pdf",3041343,"English","# Abstract\n# Keywords\n# 1. Introduction","[{\"question\":\"Why are DNA vaccines considered promising but limited in cancer immunotherapy?\",\"answer\":\"DNA vaccines can activate antigen-specific cellular immunity, but their effectiveness is often hindered by weak immunogenicity, leading to modest therapeutic outcomes across cancers.\"},{\"question\":\"What role do Type 1 conventional dendritic cells (cDC1) play in DNA vaccine efficacy?\",\"answer\":\"cDC1 cross-present vaccine antigens to activate CD8+ T cells, making them crucial for the antitumor function of DNA vaccines.\"},{\"question\":\"How does combining the cDC1-targeted DNA vaccine with gemcitabine and anti-PD1 affect outcomes in the mouse lung cancer model?\",\"answer\":\"The combination improves antitumor effect and enhances survival in the mouse lung cancer model, compared with the vaccine approach alone.\"}]","The XCL1-Mediated DNA Vaccine Targeting Type 1 Conventional Dendritic Cells Combined with Gemcitabine and Anti-PD1 Antibody Induces Potent Antitumor Immunity in a Mouse Lung Cancer Model | PDF",1790046830,35,[147,151],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/0322c65f94f6d66e8bb654e677f732a1.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/e07cd89f3df4bb7fc0763f16d3cc375a.webp",982,1388]